Vertex Kidney Disease Drug Faces FDA Decision in November

Vertex Pharmaceuticals has moved a step closer to bringing a new treatment option to patients with immunoglobulin A nephropathy (IgAN) after the U.S. Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) for povetacicept, an investigational therapy designed to target key drivers of the disease.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept would become the first commercialized product in Vertex’s growing nephrology portfolio and could offer a new treatment option for patients living with the chronic kidney disease.

IgA nephropathy, also known as Berger’s disease, is a progressive kidney disorder caused by the buildup of immunoglobulin A (IgA) deposits in the kidneys. Over time, the condition can lead to inflammation, impaired kidney function, and ultimately kidney failure. Despite recent advances in treatment, many patients continue to face a significant risk of disease progression, highlighting the need for additional therapeutic options.

Povetacicept is an engineered fusion protein that simultaneously inhibits two cytokines, BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), which play important roles in the abnormal immune responses associated with IgAN. By targeting both pathways, the therapy is designed to reduce the production of disease-driving antibodies and slow kidney damage.

The regulatory submission is supported by positive results from a pre-specified Week 36 interim analysis of the Phase 3 RAINIER study, currently the largest clinical trial conducted in IgAN. According to Vertex, the trial reached full enrollment faster than any comparable contemporary study, reflecting both the urgent need for new therapies and strong interest from the patient community.

The study achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in proteinuria, a key indicator of kidney disease progression. Patients treated with povetacicept experienced a 52% reduction from baseline in urine protein-to-creatinine ratio (UPCR) at Week 36. Compared with placebo, the treatment achieved a nearly 50% reduction in proteinuria, a result that was highly statistically significant.

The trial also met important secondary endpoints. Patients receiving povetacicept showed substantial reductions in galactose-deficient IgA1 (Gd-IgA1), a biomarker closely linked to disease activity. Treatment resulted in a 77.4% reduction from baseline, compared with a slight increase in the placebo group.

In addition, among patients who had blood in their urine at the start of the study, more than 85% of those treated with povetacicept achieved resolution of hematuria, compared with just over 23% in the placebo group. Hematuria is another important marker of kidney damage in IgAN and is often associated with disease progression.

Safety findings from the trial were also encouraging. Vertex reported that povetacicept was generally well tolerated, with most adverse events classified as mild to moderate. No serious adverse events related to the treatment were observed. While anti-drug antibodies were detected, the company stated that they did not affect the drug’s efficacy or safety profile.

Vertex plans to commercialize the therapy as a low-volume subcutaneous auto-injector administered once every four weeks at home if regulatory approval is granted. The convenient dosing schedule could provide an advantage for patients seeking long-term disease management.

Nia Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex, said the FDA’s acceptance of the application represents an important milestone in the company’s efforts to transform care for patients with IgAN. She highlighted the therapy’s potential best-in-class profile and patient-friendly administration approach.

With the FDA review now underway, the nephrology community will be closely watching the agency’s decision later this year. If approved, povetacicept could become a significant new treatment option in a disease area where unmet medical need remains substantial and long-term kidney preservation remains a primary goal.